
Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA.
The industry group has published Analysis of Health Budget Practices in eight Latin American Countries, a report funded by FIFARMA and prepared by Duke University’s Global Health Innovation Center. It examines health budget planning, allocation and execution in Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico and Peru.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze